DNAJC6 Gene

DNAJC6 Gene — DNAJ Heat Shock Protein Family (Hsp40) Member C6

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DNAJC6 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>DNAJC6</td></tr>
<tr><td><strong>Full Name</strong></td><td>DNAJ Heat Shock Protein Family (Hsp40) Member C6</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>1p31.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[9837](https://www.ncbi.nlm.nih.gov/gene/9837)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[618375](https://www.omim.org/entry/618375)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000138231</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O75037](https://www.uniprot.org/uniprot/O75037)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Early-Onset Parkinson's Disease, Atypical Parkinsonism, Juvenile Parkinsonism</td></tr>
</table>
</div>

Overview

DNAJC6 (DNAJ Heat Shock Protein Family (Hsp40) Member C6), also known as Auxilin-1, is a critical neuronal gene located on chromosome 1p31.3 that encodes a co-chaperone protein essential for synaptic vesicle recycling and protein quality control. The gene encodes a 935-amino acid protein with a molecular weight of approximately 104 kDa, containing an N-terminal co-chaperone J domain, a central client-binding region, and a C-terminal clathrin-binding domain[^1][^2].

DNAJC6 Gene — DNAJ Heat Shock Protein Family (Hsp40) Member C6

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DNAJC6 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>DNAJC6</td></tr>
<tr><td><strong>Full Name</strong></td><td>DNAJ Heat Shock Protein Family (Hsp40) Member C6</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>1p31.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[9837](https://www.ncbi.nlm.nih.gov/gene/9837)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[618375](https://www.omim.org/entry/618375)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000138231</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O75037](https://www.uniprot.org/uniprot/O75037)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Early-Onset Parkinson's Disease, Atypical Parkinsonism, Juvenile Parkinsonism</td></tr>
</table>
</div>

Overview

DNAJC6 (DNAJ Heat Shock Protein Family (Hsp40) Member C6), also known as Auxilin-1, is a critical neuronal gene located on chromosome 1p31.3 that encodes a co-chaperone protein essential for synaptic vesicle recycling and protein quality control. The gene encodes a 935-amino acid protein with a molecular weight of approximately 104 kDa, containing an N-terminal co-chaperone J domain, a central client-binding region, and a C-terminal clathrin-binding domain[^1][^2].

DNAJC6 is expressed predominantly in neuronal tissues, with highest expression in the [substantia nigra pars compacta](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [hippocampus](/brain-regions/hippocampus), and cerebral [cortex](/brain-regions/cortex)[^3]. The protein localizes to presynaptic terminals where it performs essential functions in clathrin-mediated endocytosis, the primary mechanism by which synaptic vesicles are recycled after neurotransmitter release.

Mutations in DNAJC6 cause autosomal recessive early-onset Parkinson's disease (PD), typically presenting before age 20 with an excellent response to levodopa therapy. This identification of DNAJC6 as a PD gene has provided important insights into the role of synaptic vesicle endocytosis in neurodegeneration[^4][^5].

Molecular Biology

Gene Structure and Protein Domain Architecture

The DNAJC6 gene spans approximately 35 kb and consists of 15 exons. The encoded protein, auxilin-1, contains several functional domains:

• J Domain (aa 1-70): The N-terminal J domain is conserved across all DNAJ/Hsp40 family members and functions to stimulate the ATPase activity of Hsp70 chaperones. This domain contains the highly conserved HPD motif (His-Pro-Asp) essential for Hsp70 interaction[^6].
• Client-Binding Region (aa 200-500): This region contains multiple glycine-phenylalanine (GF)-rich sequences that facilitate binding to a broad range of client proteins, including components of the clathrin coat machinery.
• Clathrin-Binding Domain (aa 600-700): The C-terminal region contains multiple clathrin box motifs (LLDLF) that enable direct binding to the clathrin triskelion, essential for the protein's role in clathrin uncoating[^7].
• Phosphorylation Sites: Multiple serine/threonine phosphorylation sites regulate the protein's activity throughout the cell cycle and during synaptic activity.

Expression Patterns

DNAJC6 shows tissue-specific expression with highest levels in neuronal tissues:

| Tissue Type | Expression Level | Localization |
|------------|------------------|--------------|
| Substantia nigra | Very High | Dopaminergic neurons |
| Striatum | High | Medium spiny neurons |
| Hippocampus | High | CA1-CA3 pyramidal cells |
| Cerebral cortex | High | Layer 5 pyramidal neurons |
| Testis | Moderate | Spermatogenic cells |
| Kidney | Low | Tubular cells |

Within neurons, DNAJC6 localizes to:

• Cytosolic compartments
• Synaptic vesicle membranes
• Clathrin-coated pits and vesicles
• Presynaptic active zones

Function

Role in Clathrin-Mediated Endocytosis

DNAJC6/Auxilin-1 plays a pivotal role in synaptic vesicle recycling through its involvement in clathrin-mediated endocytosis (CME). The process of synaptic vesicle recycling is essential for maintaining neurotransmitter release during sustained neuronal activity, as each vesicle fusion event requires the retrieval and reuse of synaptic vesicle components[^8].

The mechanism of DNAJC6 function involves:

Protein Quality Control

Beyond its role in endocytosis, DNAJC6 functions as a co-chaperone in protein quality control systems:

• Folding Assistance: The J domain facilitates proper protein folding by coordinating with Hsp70/Hsp90 machinery
• Refolding of Stress-Denatured Proteins: Under cellular stress conditions, DNAJC6 assists in the refolding of denatured proteins
• Targeting to Degradation: When refolding fails, DNAJC6 helps target misfolded proteins to the proteasome for degradation

Interaction Network

DNAJC6 interacts with multiple protein partners essential for its function:

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| HSPA8 (Hsc70) | Co-chaperone | Clathrin uncoating |
| HSPA1A (Hsp70-1) | Co-chaperone | Stress response |
| DNAJA1 (Hsp40) | Co-chaperone | Chaperone complex formation |
| CLTC (Clathrin heavy chain) | Direct binding | Coat assembly/uncoating |
| AP2 complex | Indirect | Endocytic adaptor |
| SYNJ1 (Synaptojanin 1) | Functional | Phosphoinositide metabolism |
| DNM1L (Dynamin 1) | Functional | Vesicle scission |

Disease Associations

Early-Onset Parkinson's Disease (PD)

DNAJC6 mutations were first identified as a cause of autosomal recessive early-onset Parkinson's disease in 2014[^4]. The disease typically presents in adolescence or early adulthood (before age 20) with the following characteristics:

Clinical Features:

• Progressive parkinsonism with bradykinesia, rigidity, and tremor
• Excellent levodopa response
• Early-onset gait disturbance
• Dystonia (particularly in lower extremities)
• Mild cognitive impairment in some cases
• Sleep disturbances including REM sleep behavior disorder

The identification of DNAJC6 as a PD gene was significant because it highlighted the importance of synaptic vesicle endocytosis in dopaminergic neuron survival. Unlike other PD genes involved in mitochondrial function (like [PARK2](/genes/park2) and [PINK1](/genes/pink1)), DNAJC6 links neurodegeneration to the endolysosomal pathway[^12].

Juvenile Parkinsonism

Homozygous or compound heterozygous DNAJC6 mutations cause a distinct form of juvenile parkinsonism with particularly severe early-onset symptoms. Key features include:

• Onset before age 10 in severe cases
• Prominent dystonia
• Marked developmental delay in some cases
• Excellent levodopa response but with early motor complications
• Progressive but often more benign course than typical early-onset PD[^13]

Atypical Parkinsonism

Heterozygous DNAJC6 variants may act as susceptibility factors for atypical parkinsonian disorders. Studies have identified DNAJC6 variants in patients with:

• Progressive supranuclear palsy (PSP)
• Multiple system atrophy (MSA)
• Corticobasal degeneration (CBD)

Mechanisms of Neurodegeneration

Endocytic Dysfunction

The primary mechanism by which DNAJC6 mutations cause neurodegeneration is through impaired synaptic vesicle endocytosis. Several studies have demonstrated:

Lipid Metabolism Dysregulation

A key finding from recent research is that DNAJC6 mutations cause lipid defects that contribute to neurodegeneration:

• Phosphoinositide Metabolism: DNAJC6 interacts with SYNJ1 (Synaptojanin 1), a phosphoinositide phosphatase critical for endocytic trafficking. Mutations in both genes cause similar neurodegenerative phenotypes[^16].
• Cholesterol Homeostasis: Loss of DNAJC6 disrupts cellular cholesterol distribution, affecting membrane composition and signaling.
• Lipid Raft Disruption: The lipid composition of synaptic membranes is altered, affecting receptor signaling and vesicle trafficking.

Alpha-Synuclein Pathology

DNAJC6 deficiency leads to upregulation of pathological alpha-synuclein:

• Increased alpha-synuclein expression and aggregation
• Enhanced phosphorylation at Ser129 (the key pathological modification)
• Cathepsin D downregulation, impairing lysosomal clearance of alpha-synuclein
• Spreading of alpha-synuclein pathology to neighboring neurons[^17]

Therapeutic Approaches

Gene Therapy

Given the monogenic nature of DNAJC6-associated parkinsonism, gene therapy represents a promising therapeutic approach:

• AAV-Mediated Delivery: Adeno-associated virus (AAV) vectors can deliver functional DNAJC6 to affected brain regions
• Target Regions: Substantia nigra pars compacta and striatum are primary targets
• Preclinical Results: Studies in auxilin-knockout mice demonstrate that gene therapy can rescue synaptic defects and prevent neurodegeneration[^18]

Small Molecule Interventions

Several pharmacological strategies are under investigation:

• Chaperone Modulators: Small molecules that enhance Hsp70 activity could partially compensate for DNAJC6 loss
• Endocytic Modulators: Compounds that enhance alternative endocytic pathways
• Lipid Metabolism Modulators: Drugs targeting phosphoinositide pathways
• Alpha-Synuclein-Targeting Agents: Immunotherapies and aggregation inhibitors

Symptomatic Treatment

Current clinical management includes:

• Levodopa/carbidopa (highly effective in DNAJC6-related parkinsonism)
• Dopamine agonists (pramipexole, ropinirole)
• MAO-B inhibitors (selegiline, rasagiline)
• Physical and occupational therapy

Animal Models

Mouse Models

Several mouse models have been developed to study DNAJC6 function:

• Conditional Knockout: Neuron-specific deletion of DNAjc6 leads to progressive motor deficits
• Knock-in Models: PD-associated point mutations introduced into mouse genome
• Phenotype: Auxilin-knockout mice show impaired pre-synaptic plasticity, visual response deficits, and age-dependent neurodegeneration[^19]

Zebrafish Models

Zebrafish provide a complementary model for studying DNAJC6 function during development:

• Morpholino knockdown recapitulates PD-like phenotypes
• Allows high-throughput drug screening
• Transparent embryos enable visualization of neuronal development

Genetics and Population Studies

Population Frequency

DNAJC6 pathogenic variants are rare in the general population:

• Carrier frequency: <0.001% for pathogenic variants
• Founder mutations identified in specific populations
• Higher prevalence in consanguineous families

Genotype-Phenotype Correlations

| Genotype | Phenotype Severity | Age of Onset |
|----------|-------------------|--------------|
| Two truncating mutations | Severe | <10 years |
| One truncating + one missense | Moderate | 10-20 years |
| Two missense mutations | Mild | 15-25 years |
| Heterozygous | Variable | Adult |

Key Publications

See Also

• [DNAJC6 Protein](/proteins/dnajc6-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Synaptic Vesicle Recycling](/mechanisms/synaptic-vesicle-recycling)
• [Hsp40 Chaperones](/mechanisms/chaperone-proteins)
• [Endocytosis](/mechanisms/endocytosis)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [SYNJ1 Gene](/genes/synj1)
• [Clathrin-Mediated Endocytosis](/mechanisms/clathrin-mediated-endocytosis)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Juvenile Parkinsonism](/diseases/juvenile-parkinsonism)

References

External Links

• [NCBI Gene: DNAJC6](https://www.ncbi.nlm.nih.gov/gene/9837)
• [OMIM: 618375](https://www.omim.org/entry/618375)
• [UniProt: O75037](https://www.uniprot.org/uniprot/O75037)
• [Ensembl: ENSG00000138231](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138231)
• [PubMed: DNAJC6 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=DNAJC6+neurodegeneration)